# Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting

> **NCT05079113** · — · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 73 (actual)

## Conditions studied

- Stage III Melanoma
- Stage IV Cutaneous Melanoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05079113
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-01
- **Primary completion:** 2023-04-04
- **Final completion:** 2023-04-04
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2024-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05079113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05079113, "Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05079113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*